This is a randomised, placebo-controlled, double-blind 3-way crossover study in which
PUR1800, or placebo is dosed daily for 14 consecutive days in adult subjects with stable COPD
over three discrete TPs. Subjects will be randomised to one of the following 3 treatment
sequences:
Sequence Period 1 Period 2 Period 3
1. Placebo PUR1800 250 μg PUR1800 500 μg
2. PUR1800 250 μg Placebo PUR1800 500 μg
3. PUR1800 250 μg PUR1800 500 μg Placebo
Since this is the first study in humans in which the iSPERSE formulation is being
administered, the 3 treatment sequences are designed in order to ensure that the lower dose
of PUR1800 (250 μg) is administered prior to the administration of the higher dose of PUR1800
(500 μg).